非何杰金氏淋巴瘤治疗市场（按治疗类型、细胞类型、给药途径、患者年龄层和最终用户划分）—2025-2032 年全球预测

预计到 2032 年非何杰金氏淋巴瘤治疗市场将成长至 188.3 亿美元，复合年增长率为 8.97%。

多方面的临床、监管和商业性力量决定了非何杰金氏淋巴瘤的治疗策略

非何杰金氏淋巴瘤代表一组形态各异的骨髓恶性肿瘤，持续对临床医师、支付者和创新者构成挑战。免疫疗法、分子标靶药物和细胞疗法的最新进展重新定义了多种亚型的临床治疗路径，而诊断和风险分层工具的改进也使得更个人化的治疗方法成为可能。本介绍提供了临床、监管和商业性背景，以支援研发和上市团队目前的策略决策。

不断发展的治疗模式正在推动肿瘤学家、血液学家和相关专家之间的多学科合作，为整个医疗领域带来了机会和挑战。医疗保健系统难以将高成本、高疗效的治疗方法纳入现有的方案和护理路径，而支付方也越来越重视真实世界证据和基于价值的安排。因此，相关人员必须应对不断变化的报销环境、倾向于加速核准的监管趋势以及新型作用机制的竞争动态。本节重点在于临床创新与商业性准备的交汇，为后续的详细分析奠定基础，这些分析将塑造近期的策略。

确定关键的临床、监管和商业转型，重新定义非何杰金氏淋巴瘤治疗的开发和应用

非何杰金氏淋巴瘤的治疗格局正被多种力量汇聚而成，这些力量正在改变治疗方法的开发、核准和应用方式。首先，精准医疗和分子分析正从小众领域走向主流，使得B细胞、T细胞和NK细胞淋巴瘤的分类更加精细，并为标靶标靶治疗方法提供资讯。其次，细胞疗法和双特异性抗体的成熟，正在扩大治癒和持久缓解的可能性，超越传统的化疗和放射线治疗，促使人们重新评估治疗顺序和联合策略。

同时，法律规范也在不断发展，以适应加速审批流程和有条件核准，这增加了核准后证据产生的重要性。健康技术评估流程正在适应新的终点和病患报告结果，重塑证据产生规划。在商业性方面，生物技术创新者与成熟製药公司之间的伙伴关係正在加速后期开发和全球商业化，而数位疗法和远端医疗正在加强患者监测和生存期护理。总而言之，这些转变需要一项涵盖临床开发、真实世界证据、定价和相关人员参与的整合策略，以充分发挥新治疗方法的潜力。

评估2025年美国关税调整对供应链弹性、成本管理和商业性准入策略的多面向影响

2025年影响贸易和进口关税的政策变化，为医药供应链、定价策略和跨境临床试验物流规划带来了新的变数。关税调整可能会影响原料药、生技药品成品和医疗设备的到达成本，迫使製造商重新评估筹资策略和库存配置。为此，企业正在加快供应链恢復工作，包括双重采购、关键零件近岸外包以及策略性储备，以减轻潜在的中断和成本增加。

除了直接的成本影响外，关税还会透过改变支付方和医疗服务提供者之间的净定价和报销谈判，影响商业策略。製药公司越来越多地参与情境规划，以了解关税引发的成本压力将如何影响合约谈判和竞标结果。此外，为了最大限度地降低关税波动的影响，临床开发和生产领域的跨国合作正在重新评估。这些累积效应使得製药公司更加重视灵活的生产方式、多元化的供应商网络以及与相关人员的主动沟通，以保障非何杰金氏淋巴瘤患者的治疗可及性和持续性。

整合治疗方式、细胞亚型、给药途径、患者人口统计和医疗保健环境的可操作细分洞察

准确了解临床和商业细分市场对于使开发项目和商业发布计划与未满足的需求和治疗途径保持一致至关重要。基于治疗类型的分析考虑了化疗、免疫疗法、放射放射线治疗、干细胞移植和标靶治疗，以及每种疗法如何与目前方案中的定序、联合治疗潜力和耐受性相互作用。 B 细胞淋巴瘤进一步分为套件淋巴瘤、瀰漫大 B 细胞淋巴瘤 (DLBCL) 和滤泡性淋巴瘤，而 T 细胞淋巴瘤进一步分为异生性大细胞淋巴瘤、皮肤 T 细胞淋巴瘤和周边 T 细胞淋巴瘤，每种淋巴瘤都代表着不同的治疗需求和临床试验考虑因素。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• CAR-T细胞疗法的快速普及推动了復发和难治性非何杰金氏淋巴瘤治疗模式转移
• 双特异性抗体疗法的出现扩大了侵袭性 B 细胞淋巴瘤的现成免疫疗法选择
• 整合微量残存疾病监测来指导滤泡性淋巴瘤治疗的个人化维护策略
• 小分子标靶抑制剂的扩展增强了惰性和进行性非何杰金氏淋巴瘤一线治疗的联合治疗
• 扩大抗体药物复合体在提高復发性瀰漫大B细胞淋巴瘤的缓解率和降低毒性方面的作用
• 开发新型表观调变器，为难治性周边区域淋巴瘤提供新的治疗途径
• 数位诊断与人工智慧驱动的生物标记的增强整合将加速非何杰金氏淋巴瘤的早期发现和个人化治疗
• 支付方和报销趋势影响淋巴瘤治疗中昂贵的免疫疗法和生物相似药的可及性
• 双特异性抗体的出现彻底改变了復发性非何杰金氏淋巴瘤的治疗模式
• CAR-T 细胞疗法的广泛应用显着改善了侵袭性 NHL 亚型的治疗效果

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

非何杰金氏淋巴瘤治疗市场（依治疗类型）

• 化疗
• 免疫疗法
• 放射治疗
• 干细胞移植
• 标靶治疗

非何杰金氏淋巴瘤治疗市场（依细胞类型）

• B细胞淋巴瘤
  • 套件淋巴瘤
  • 瀰漫大B细胞淋巴瘤（DLBCL）
  • 滤泡性淋巴瘤
  • 套细胞淋巴瘤
  • 周边区域淋巴瘤
• NK细胞淋巴瘤
• T细胞淋巴瘤
  • 异生性大细胞淋巴瘤
  • 皮肤T细胞淋巴瘤
  • 週边T细胞淋巴瘤

非何杰金氏淋巴瘤治疗市场

• 静脉输液
• 口服
• 皮下注射

非何杰金氏淋巴瘤治疗市场（依患者年龄层）

• 成人
• 老年人
• 孩子们

非何杰金氏淋巴瘤治疗市场（依最终用户）

• 门诊手术中心
• 癌症治疗中心
• 医院

非何杰金氏淋巴瘤治疗市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

非何杰金氏淋巴瘤治疗市场：按组

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

非何杰金氏淋巴瘤治疗市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Kyowa Kirin Co., Ltd.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals

The Non-Hodgkin Lymphoma Treatment Market is projected to grow by USD 18.83 billion at a CAGR of 8.97% by 2032.

A comprehensive orientation to the multifaceted clinical, regulatory, and commercial forces shaping Non-Hodgkin Lymphoma treatment strategies across care settings

Non-Hodgkin Lymphoma represents a diverse group of hematologic malignancies that continues to challenge clinicians, payers, and innovators in equal measure. Recent advances in immunotherapies, targeted agents, and refinements in cellular therapies have rewritten clinical pathways for many subtypes, while diagnostic improvements and risk stratification tools are enabling more personalized approaches to care. This introduction establishes the clinical, regulatory, and commercial context that underpins current strategic decision-making across research, development, and market access teams.

The evolving treatment paradigm has created opportunities and complexities across care settings, prompting multidisciplinary collaboration among oncologists, hematologists, and allied specialists. Health systems are grappling with integrating high-cost, high-impact therapies into existing formularies and care pathways, and payers are increasingly focused on real-world evidence and value-based arrangements. Consequently, stakeholders must navigate shifting reimbursement environments, regulatory pathways that prioritize accelerated approvals, and competitive dynamics driven by novel mechanisms of action. This section sets the stage for the deeper analysis that follows, highlighting the intersections of clinical innovation and commercial readiness that will shape near-term strategy.

Identifying the pivotal clinical, regulatory, and commercial transformations that are redefining therapeutic development and adoption in Non-Hodgkin Lymphoma care

The landscape for Non-Hodgkin Lymphoma treatment is being transformed by several convergent forces that are altering how therapies are developed, approved, and adopted. First, precision medicine and molecular profiling have moved from niche to mainstream, enabling more granular classification of B-cell, T-cell, and NK-cell lymphomas and informing targeted therapeutic approaches. Second, the maturation of cellular therapies and bispecific antibodies is expanding curative and durable response possibilities beyond traditional chemotherapy and radiation, prompting a re-evaluation of sequencing and combination strategies.

Simultaneously, regulatory frameworks are evolving to accommodate accelerated pathways and conditional approvals, increasing the importance of post-approval evidence generation. Health technology assessment processes are adapting to novel endpoints and patient-reported outcomes, which is reshaping evidence generation plans. On the commercial front, partnerships between biotech innovators and established pharmaceutical companies are accelerating late-stage development and global commercialization, while digital therapeutics and telehealth are enhancing patient monitoring and survivorship care. Taken together, these shifts demand integrated strategies that span clinical development, real-world evidence, pricing, and stakeholder engagement to realize the full potential of new therapies.

Evaluating the multifaceted repercussions of United States tariff adjustments in 2025 on supply chain resilience, cost management, and commercial access strategies

Policy changes affecting trade and import tariffs in 2025 have introduced new variables into planning for drug supply chains, pricing strategies, and cross-border clinical trial logistics. Tariff adjustments can influence the landed cost of active pharmaceutical ingredients, finished biologics, and medical devices, leading manufacturers to reassess sourcing strategies and inventory positioning. In response, organizations are accelerating supply-chain resilience efforts, including dual-sourcing, nearshoring of critical components, and strategic stockpiling to mitigate the potential for disruption and cost escalation.

Beyond direct cost impacts, tariffs influence commercial strategies by altering net pricing calculations and reimbursement negotiations across payers and providers. Pharmaceutical companies are increasingly engaging in scenario planning to understand how incremental tariff-driven cost pressures could affect contract negotiations and tender outcomes. Additionally, cross-border collaborations in clinical development and manufacturing are being reevaluated to minimize exposure to tariff volatility. The cumulative effect is a heightened emphasis on flexible manufacturing, diversified supplier networks, and proactive stakeholder communication to preserve access and maintain the continuity of care for patients with Non-Hodgkin Lymphoma.

Actionable segmentation insights that integrate treatment modalities, cellular subtypes, administration routes, patient age demographics, and healthcare delivery settings

A precise understanding of clinical and commercial segments is essential to align development programs and commercial launch plans with unmet need and care pathways. Based on Treatment Type, analysis considers Chemotherapy, Immunotherapy, Radiation Therapy, Stem Cell Transplant, and Targeted Therapy and how each modality interacts with sequencing, combinability, and tolerability in contemporary regimens. Based on Cell Type, differentiation among B-cell Lymphomas, NK-cell Lymphomas, and T-cell Lymphomas is central to strategy, with B-cell Lymphomas further broken down into Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, and Marginal Zone Lymphoma, and T-cell Lymphomas further categorized into Anaplastic Large Cell Lymphoma, Cutaneous T-Cell Lymphoma, and Peripheral T-Cell Lymphoma, each presenting distinct therapeutic needs and clinical trial considerations.

Based on Route of Administration, distinctions between Intravenous Infusion, Oral, and Subcutaneous Injection influence patient preference, adherence, and site-of-care economics. Based on Patient Age Group, the adult, geriatric, and pediatric populations exhibit varying comorbidity profiles, tolerability constraints, and long-term survivorship considerations that should inform dosing strategies and safety monitoring plans. Based on End User, differences in care delivery across Ambulatory Surgical Centers, Cancer Treatment Centers, and Hospitals affect reimbursement pathways, capacity planning, and clinician adoption patterns. Integrating these segmentation layers enables targeted clinical development, differentiated value propositions, and nuanced go-to-market planning.

Deep regional intelligence highlighting regulatory nuance, evidence priorities, and access pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics play a critical role in shaping regulatory strategies, clinical development priorities, and commercialization pathways for Non-Hodgkin Lymphoma therapies. In the Americas, regulatory authorities and payer systems present a mix of accelerated approval mechanisms and rigorous health technology assessment processes, driving a dual focus on breakthrough designation strategies and robust real-world evidence generation. In Europe, Middle East & Africa, heterogeneous regulatory environments and disparities in access necessitate tailored market entry plans, adaptive pricing strategies, and regional partnerships to optimize uptake and patient access.

In the Asia-Pacific region, rapid expansion of clinical research capacity, growing domestic biopharma innovation, and evolving reimbursement frameworks are creating both opportunity and complexity. Local manufacturing, regional clinical trial networks, and government-led initiatives to improve cancer outcomes are shaping pathways to adoption. Across all regions, cross-border collaboration, regulatory harmonization efforts, and the localization of evidence packages are increasingly important to ensure timely approval and sustainable access. Understanding these regional nuances is essential for designing regulatory submission strategies, evidence generation plans, and commercial approaches that are responsive to local healthcare infrastructures and payer expectations.

Strategic competitive intelligence outlining how incumbent pharmaceutical groups and nimble innovators are shaping differentiation through evidence, partnerships, and delivery models

Competitive dynamics in Non-Hodgkin Lymphoma treatment are characterized by a blend of legacy oncology players and agile innovators advancing novel modalities. Established pharmaceutical companies remain critical in late-stage development, global commercialization, and manufacturing scale-up, while smaller biotechs often drive early innovation in bispecifics, ADCs, and cellular platforms. Collaborations, licensing deals, and strategic alliances are common, enabling nimble companies to leverage larger partners' regulatory and commercial expertise and enabling incumbents to refresh pipelines with innovative mechanisms of action.

The competitive landscape also reflects differentiation through evidence generation strategies, including pivotal trials focused on durable endpoints, real-world evidence programs to demonstrate effectiveness in broader populations, and biomarker-driven development to improve patient selection. Manufacturers are investing in patient support programs, hub services, and digital health tools to optimize adherence and streamline administration. As competition intensifies, companies that can demonstrate clear clinical differentiation, robust safety profiles, and pragmatic implementation models across diverse care settings will be positioned to capture clinician preference and payer support.

Practical and prioritized recommendations for industry leaders to synchronize clinical development, evidence generation, and market access strategies for durable impact

Industry leaders should prioritize an integrated strategy that aligns scientific development with commercial and access readiness. First, invest in robust biomarker and diagnostics strategies early to ensure precise patient selection and to improve the probability of regulatory success and payer acceptance. Second, design evidence-generation plans that combine randomized trials with prospective real-world studies and health economics analyses to support both regulatory approval and favorable reimbursement decisions. Third, strengthen supply chain resilience through diversified sourcing, flexible manufacturing, and contingency planning to mitigate policy-driven cost pressures and logistical disruptions.

In parallel, develop differentiated value propositions that articulate not only clinical benefits but also system-level value such as reduced hospitalizations and improved quality of life. Engage early with payers, HTA bodies, and provider networks to co-create reimbursement pathways, including outcomes-based arrangements where appropriate. Finally, foster partnerships across the ecosystem-academic centers, contract manufacturers, diagnostics providers, and patient advocacy organizations-to accelerate evidence generation and streamline adoption. These combined actions will help organizations translate therapeutic innovation into durable clinical and commercial impact.

Transparent multi-method research approach combining secondary synthesis and primary stakeholder engagement to validate clinical and commercial insights

The research underpinning this report combines comprehensive secondary analysis with targeted primary engagements to ensure rigor and relevance. Secondary inputs include peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and payer policy publications, all synthesized to map clinical pathways, approval landscapes, and evidence gaps. Primary research incorporates structured interviews with key opinion leaders, treating physicians, payers, and patient advocacy representatives to capture nuanced perspectives on treatment preferences, barriers to adoption, and unmet needs.

Data triangulation methods were applied to reconcile divergent inputs and validate thematic conclusions. Analytical techniques included cross-validation of clinical outcomes with real-world treatment patterns, assessment of regulatory precedents against current development programs, and synthesis of commercial strategies through case-based benchmarking. Quality controls included independent expert review and an internal verification process to ensure consistency and transparency. This mixed-method approach ensures that the insights presented are grounded in clinical reality, reflective of stakeholder priorities, and actionable for strategic decision-making.

Concluding synthesis highlighting how integrated evidence, operational agility, and stakeholder engagement will determine the pace of therapeutic impact in Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma treatment is at a transformative juncture driven by targeted therapies, immunologic approaches, and more precise diagnostic frameworks. These advances offer the potential to improve patient outcomes and redefine standard-of-care sequences, yet they also introduce complexities in evidence requirements, pricing discussions, and operational readiness. Successful navigation will require coordinated strategies across development, regulatory engagement, payer interactions, and provider adoption efforts.

Looking ahead, organizations that embrace integrated evidence generation, invest in supply chain agility, and actively engage stakeholders across regions will be better positioned to translate innovation into sustainable clinical impact. The convergence of scientific progress and changing commercial dynamics presents both opportunities and responsibilities: to design therapies that meet unmet needs, to generate the evidence required for broad access, and to implement delivery models that ensure equitable patient benefit. This conclusion underscores the imperative for strategic alignment and timely action to realize the promise of new treatments for patients living with Non-Hodgkin Lymphoma.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rapid adoption of CAR T-cell therapies driving treatment paradigm shifts in relapsed and refractory non-Hodgkin lymphoma
• 5.2. Emergence of bispecific antibody therapies expanding off-the-shelf immunotherapy options for aggressive B-cell lymphomas
• 5.3. Integration of minimal residual disease monitoring guiding personalized maintenance strategies in follicular lymphoma management
• 5.4. Expansion of targeted small molecule inhibitors enhancing frontline combination regimens in indolent and aggressive non-Hodgkin lymphoma subtypes
• 5.5. Growing role of antibody-drug conjugates improving response rates and reducing toxicity in relapsed diffuse large B-cell lymphoma
• 5.6. Development of novel epigenetic modulators offering new therapeutic pathways for treatment-resistant marginal zone lymphoma cases
• 5.7. Increased integration of digital diagnostics and AI-driven biomarkers accelerating early detection and therapy customization in non-Hodgkin lymphoma
• 5.8. Payer and reimbursement dynamics shaping access to high-cost immunotherapies and biosimilars in lymphoma care across global markets
• 5.9. Emergence of bispecific antibodies revolutionizing treatment paradigms for relapsed non-Hodgkin lymphoma
• 5.10. Rising adoption of CAR T-cell therapies significantly improving outcomes in aggressive NHL subtypes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type

• 8.1. Chemotherapy
• 8.2. Immunotherapy
• 8.3. Radiation Therapy
• 8.4. Stem Cell Transplant
• 8.5. Targeted Therapy

9. Non-Hodgkin Lymphoma Treatment Market, by Cell Type

• 9.1. B-cell Lymphomas
  • 9.1.1. Burkitt Lymphoma
  • 9.1.2. Diffuse Large B-Cell Lymphoma (DLBCL)
  • 9.1.3. Follicular Lymphoma
  • 9.1.4. Mantle Cell Lymphoma
  • 9.1.5. Marginal Zone Lymphoma
• 9.2. NK-cell Lymphomas
• 9.3. T-cell Lymphomas
  • 9.3.1. Anaplastic Large Cell Lymphoma
  • 9.3.2. Cutaneous T-Cell Lymphoma
  • 9.3.3. Peripheral T-Cell Lymphoma

10. Non-Hodgkin Lymphoma Treatment Market, by Route of Administration

• 10.1. Intravenous Infusion
• 10.2. Oral
• 10.3. Subcutaneous Injection

11. Non-Hodgkin Lymphoma Treatment Market, by Patient Age Group

• 11.1. Adult
• 11.2. Geriatric
• 11.3. Pediatric

12. Non-Hodgkin Lymphoma Treatment Market, by End User

• 12.1. Ambulatory Surgical Centers
• 12.2. Cancer Treatment Centers
• 12.3. Hospitals

13. Non-Hodgkin Lymphoma Treatment Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Non-Hodgkin Lymphoma Treatment Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Non-Hodgkin Lymphoma Treatment Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. AbbVie Inc.
  • 16.3.2. AstraZeneca PLC
  • 16.3.3. Bayer AG
  • 16.3.4. BeiGene, Ltd.
  • 16.3.5. Bristol-Myers Squibb Company
  • 16.3.6. Cipla Inc.
  • 16.3.7. Dr. Reddy's Laboratories Ltd.
  • 16.3.8. Eli Lilly and Company
  • 16.3.9. F. Hoffmann-La Roche Ltd
  • 16.3.10. Gilead Sciences, Inc.
  • 16.3.11. GlaxoSmithKline PLC
  • 16.3.12. Hikma Pharmaceuticals PLC
  • 16.3.13. Intas Pharmaceuticals Ltd.
  • 16.3.14. Kyowa Kirin Co., Ltd.
  • 16.3.15. Lupin Ltd.
  • 16.3.16. Merck & Co., Inc.
  • 16.3.17. Novartis AG
  • 16.3.18. Salvavidas Pharmaceutical Pvt. Ltd.
  • 16.3.19. Sanofi S.A.
  • 16.3.20. Takeda Pharmaceutical Company Limited
  • 16.3.21. Teva Pharmaceutical Industries Ltd.
  • 16.3.22. Zydus Pharmaceuticals

LIST OF FIGURES

• FIGURE 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 172. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 173. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 174. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 175. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
• TABLE 176. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
• TABLE 177. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 178. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 179. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 180. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 181. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 182. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 183. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 184. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 185. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 186. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 187. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 190. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 191. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
• TABLE 192. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
• TABLE 193. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 194. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 195. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 196. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 197. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 198. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 199. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 200. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 201. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 206. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 207. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
• TABLE 208. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
• TABLE 209. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 210. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 211. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 212. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 213. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 214. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 215. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 216. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 217. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 218. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 239. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
• TABLE 240. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
• TABLE 241. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 243. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 245. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 246. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 247. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 249. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
• TABLE 256. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
• TABLE 257. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 258. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 259. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 260. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 261. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 262. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 263. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 264. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 265. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 266. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 271. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
• TABLE 272. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
• TABLE 273. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 274. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 275. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
• TABLE 276. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
• TABLE 277. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 278. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 279. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 280. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 281. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 282. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 287. ASIA-PACIFIC NON-HODGK